Evidence map›Paper›PMID 24170107›Full record

ArticleThe Journal of clinical endocrinology and metabolism2014

Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.

Manoj Garg, Deepika Kanojia, Ryoko Okamoto, Saket Jain, Vikas Madan, Wenwen Chien, Abhishek Sampath, Ling-Wen Ding, Meng Xuan, Jonathan W Said and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Manoj GargCancer Science Institute of Singapore (M.G., D.K., S.J., V.M., W.C., A.S., LW.D., M.X., L.-Z.L., H.Y., H.P.K.), National University of Singapore, and National University Cancer Institute (H.P.K.), National University Hospital, 117599 Singapore; Division of Hematology/Oncology (R.O., S.G., H.P.K.), Cedars-Sinai Medical Center, and Departments of Pathology and Laboratory Medicine (J.W.S., N.B.D.), Medicine (G.D.B), David Geffen School of Medicine, University of California School of Medicine, Los Angeles, California 90059.
Deepika Kanojia
Ryoko Okamoto
Saket Jain
Vikas Madan
Wenwen Chien
Abhishek Sampath
Ling-Wen Ding
Meng Xuan
Jonathan W Said
Ngan B Doan
Li-Zhen Liu
Henry Yang
Sigal Gery
Glenn D Braunstein
H Phillip Koeffler
National University Cancer Institute, Singapore · SGUniversity of California, Los Angeles · USCedars-Sinai Medical Center · USNational University Hospital · SG

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

contextAnaplastic thyroid carcinoma (ATC) is an aggressive malignancy having no effective treatment. Laminin subunit-γ-2 (LAMC2) is an epithelial basement membrane protein involved in cell migration and tumor invasion and might represent an ideal target for the development of novel therapeutic approaches for ATC.

objectiveThe objective of the investigation was to study the role of LAMC2 in ATC tumorigenesis.

designLAMC2 expression was evaluated by RT-PCR, Western blotting, and immunohistochemistry in tumor specimens, adjacent noncancerous tissues, and cell lines. The short hairpin RNA (shRNA) approach was used to investigate the effect of LAMC2 knockdown on the tumorigenesis of ATC.

resultsLAMC2 was highly expressed in ATC samples and cell lines compared with normal thyroid tissues. Silencing LAMC2 by shRNA in ATC cells moderately inhibited cell growth in liquid culture and dramatically decreased growth in soft agar and in xenografts growing in immunodeficient mice. Silencing LAMC2 caused cell cycle arrest and significantly suppressed the migration, invasion, and wound healing of ATC cells. Rescue experiments by overexpressing LAMC2 in LAMC2 knockdown cells reversed the inhibitory effects as shown by increased cell proliferation and colony formation. Microarray data demonstrated that LAMC2 shRNA significantly altered the expression of genes associated with migration, invasion, proliferation, and survival. Immunoprecipitation studies showed that LAMC2 bound to epidermal growth factor receptor (EGFR) in the ATC cells. Silencing LAMC2 partially blocked epidermal growth factor-mediated activation of EGFR and its downstream pathway. Interestingly, cetuximab (an EGFR blocking antibody) or EGFR small interfering RNA additively enhanced the antiproliferative activity of the LAMC2 knockdown ATC cells compared with the control cells.

conclusionsTo our knowledge, this is the first report investigating the effect of LAMC2 on cell growth, cell cycle, migration, invasion, and EGFR signaling in ATC cells, suggesting that LAMC2 may be a potential therapeutic target for the treatment of ATC.

Indexed as

AnimalsCell MovementDisease ProgressionErbB ReceptorsGene Expression Regulation, NeoplasticHumansLamininMiceNeoplasm InvasivenessNeoplasm MetastasisRNA, Small InterferingSignal TransductionThyroid Carcinoma, AnaplasticThyroid NeoplasmsTumor Cells, CulturedXenograft Model Antitumor AssaysErbB ReceptorsLAMC2 protein, humanLamininRNA, Small Interfering

Identifiers

PMID24170107
PMCPMC3879679
OpenAlexW2095067434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.